FDA Brief

Warning letters Drugs

FDA warning letter to

Sagent Pharmaceuticals, Inc.

High riskIssued Jul 27, 2022Posted Dec 20, 2022Division Pharmaceutical Quality Operations I

FDA found SterRx, acquired by Sagent, made sterile drugs under conditions that risked contamination and lacked sterility assurance.

What happened

FDA inspected the SterRx facility in Plattsburgh, NY, from September 21 to November 4, 2021. Investigators found serious deficiencies in sterile processing, including blocked or turbulent first air, dirty equipment, and inadequate environmental monitoring. The firm stopped sterile production and recalled certain sterile lots because of lack of sterility assurance.

What FDA found

  1. FDA said first air was blocked or not provided in ISO 5 cleanroom areas where open IV bags and sterile closures were handled.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. Smoke studies showed turbulent, non-laminar air in an ISO 5 cleanroom zone near IV bag filling and sealing.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  3. The firm did not adequately evaluate or correct microbial contamination found in the ISO 5 sterile processing area.

    21 CFR 211.42(c)(10)(iv)
  4. Equipment in classified areas was visibly dirty and hard to clean, with rust, chipped paint, tape, and residue buildup.

    21 CFR 211.67(a)
  5. Sterilized equipment and utensils were stored in an unclassified transition area without an established hold time.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  6. FDA said the firm failed to ensure container closure systems protected the drug product from contamination.

    21 CFR 211.94(b)

What FDA wants

FDA asks the company to reply in writing within 15 working days with specific steps taken to address the violations, or to say that it does not intend to resume sterile drug production. If it cannot fully respond in that time, it must give the reason and a timeline.

Who should pay attention

  • hospitals and clinics that buy compounded sterile drugs
  • outsourcing facilities and sterile compounders
  • distributors or brands relying on SterRx/Sagent sterile products

This is a summary. Read the original letter on fda.gov.

Sagent Pharmaceuticals, Inc.'s FDA history

Recalls in the last 12 months

May 27 Class III Sagent Pharmaceuticals
Drug
Busulfan Injection, 60 mg per 10 mL (6 mg per mL), 8x10 mL Single-Dose Vials, Rx only, Mfd. for Sagent Pharmaceuticals, Schaumburg, IL 60195, Made in Canada, NDC 25021-241-10.
Failed Impurities/Degradation Specifications

Full company page

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk